Literature DB >> 19995899

STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model.

Vedran Radojcic1, Maria A Pletneva, Hung-Rong Yen, Sanja Ivcevic, Angela Panoskaltsis-Mortari, Anita C Gilliam, Charles G Drake, Bruce R Blazar, Leo Luznik.   

Abstract

Donor CD4+ T cells are thought to be essential for inducing delayed host tissue injury in chronic graft-versus-host disease (GVHD). However, the relative contributions of distinct effector CD4+ T cell subpopulations and the molecular pathways influencing their generation are not known. We investigated the role of the STAT3 pathway in a murine model of chronic sclerodermatous GVHD. This pathway integrates multiple signaling events during the differentiation of naive CD4+ T cells and impacts their homeostasis. We report that chimeras receiving an allograft containing STAT3-ablated donor CD4+ T cells do not develop classic clinical and pathological manifestations of alloimmune tissue injury. Analysis of chimeras showed that abrogation of STAT3 signaling reduced the in vivo expansion of donor-derived CD4+ T cells and their accumulation in GVHD target tissues without abolishing antihost alloreactivity. STAT3 ablation did not significantly affect Th1 differentiation while enhancing CD4+CD25+Foxp3+ T cell reconstitution through thymus-dependent and -independent pathways. Transient depletion of CD25+ T cells in chimeras receiving STAT3-deficient T cells resulted in delayed development of alloimmune gut and liver injury. This delayed de novo GVHD was associated with the emergence of donor hematopoietic stem cell-derived Th1 and Th17 cells. These results suggest that STAT3 signaling in graft CD4+ T cells links the alloimmune tissue injury of donor graft T cells and the emergence of donor hematopoietic stem cell-derived pathogenic effector cells and that both populations contribute, albeit in different ways, to the genesis of chronic GVHD after allogenic bone marrow transplantation in a murine model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995899      PMCID: PMC2941975          DOI: 10.4049/jimmunol.0903006

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

2.  Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease.

Authors:  Yukimi Sakoda; Daigo Hashimoto; Shoji Asakura; Kengo Takeuchi; Mine Harada; Mitsune Tanimoto; Takanori Teshima
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

Review 3.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

4.  Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

Authors:  Timothy J Harris; Joseph F Grosso; Hung-Rong Yen; Hong Xin; Marcin Kortylewski; Emilia Albesiano; Edward L Hipkiss; Derese Getnet; Monica V Goldberg; Charles H Maris; Franck Housseau; Hua Yu; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

5.  IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.

Authors:  Mika Nishihara; Hideki Ogura; Naoko Ueda; Mineko Tsuruoka; Chika Kitabayashi; Fumio Tsuji; Hiroyuki Aono; Katsuhiko Ishihara; Eric Huseby; Ulrich A K Betz; Masaaki Murakami; Toshio Hirano
Journal:  Int Immunol       Date:  2007-05-09       Impact factor: 4.823

6.  CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease.

Authors:  Yi Zhang; Elizabeth Hexner; Dale Frank; Stephen G Emerson
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

7.  Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

Authors:  Arian Laurence; Cristina M Tato; Todd S Davidson; Yuka Kanno; Zhi Chen; Zhengju Yao; Rebecca B Blank; Françoise Meylan; Richard Siegel; Lothar Hennighausen; Ethan M Shevach; John J O'shea
Journal:  Immunity       Date:  2007-03       Impact factor: 31.745

8.  Essential autocrine regulation by IL-21 in the generation of inflammatory T cells.

Authors:  Roza Nurieva; Xuexian O Yang; Gustavo Martinez; Yongliang Zhang; Athanasia D Panopoulos; Li Ma; Kimberly Schluns; Qiang Tian; Stephanie S Watowich; Anton M Jetten; Chen Dong
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

9.  IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

Authors:  Thomas Korn; Estelle Bettelli; Wenda Gao; Amit Awasthi; Anneli Jäger; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

10.  Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.

Authors:  David Askew; Lixin Zhou; Cayun Wu; Guofen Chen; Anita C Gilliam
Journal:  J Invest Dermatol       Date:  2007-04-12       Impact factor: 8.551

View more
  44 in total

1.  STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity.

Authors:  Brian C Betts; Anandharaman Veerapathran; Joseph Pidala; Xue-Zhong Yu; Claudio Anasetti
Journal:  J Leukoc Biol       Date:  2013-09-25       Impact factor: 4.962

2.  An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

Authors:  Edouard Forcade; Katelyn Paz; Ryan Flynn; Brad Griesenauer; Tohti Amet; Wei Li; Liangyi Liu; Giorgos Bakoyannis; Di Jiang; Hong Wei Chu; Mercedes Lobera; Jianfei Yang; David S Wilkes; Jing Du; Kate Gartlan; Geoffrey R Hill; Kelli Pa MacDonald; Eduardo L Espada; Patrick Blanco; Jonathan S Serody; John Koreth; Corey S Cutler; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Sophie Paczesny; Bruce R Blazar
Journal:  JCI Insight       Date:  2017-06-15

3.  C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans.

Authors:  Divya A Verghese; Nicholas Chun; Katelyn Paz; Miguel Fribourg; Trent M Woodruff; Ryan Flynn; Yuan Hu; Huabao Xiong; Weijia Zhang; Zhengzi Yi; Jing Du; Bruce R Blazar; Peter S Heeger
Journal:  JCI Insight       Date:  2018-12-20

4.  Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Stacey Tannheimer; Amy J Johnson; Shuai Dong; Anne-Katrien Stark; Klaus Okkenhaug; Angela Panoskaltsis-Mortari; Peter T Sage; Arlene H Sharpe; Leo Luznik; Jerome Ritz; Robert J Soiffer; Corey S Cutler; John Koreth; Joseph H Antin; David B Miklos; Kelli P MacDonald; Geoffrey R Hill; Ivan Maillard; Jonathan S Serody; William J Murphy; David H Munn; Colby Feser; Michael Zaiken; Bart Vanhaesebroeck; Laurence A Turka; John C Byrd; Bruce R Blazar
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

Review 5.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

6.  IL-21 Promotes Pulmonary Fibrosis through the Induction of Profibrotic CD8+ T Cells.

Authors:  Tia Y Brodeur; Tara E Robidoux; Jason S Weinstein; Joseph Craft; Susan L Swain; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

7.  Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Authors:  Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

8.  Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Authors:  Katelyn Paz; Ryan Flynn; Jing Du; Jun Qi; Leo Luznik; Ivan Maillard; Kelli P MacDonald; Geoffrey R Hill; Jonathan S Serody; William J Murphy; Peter T Sage; Arlene H Sharpe; David Miklos; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; James E Bradner; Ari M Melnick; Bruce R Blazar
Journal:  Blood       Date:  2018-10-02       Impact factor: 22.113

9.  Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity.

Authors:  Xiaohui Kong; Deye Zeng; Xiwei Wu; Bixin Wang; Shijie Yang; Qingxiao Song; Yongping Zhu; Martha Salas; Hanjun Qin; Ubaydah Nasri; Karen M Haas; Arthur D Riggs; Ryotaro Nakamura; Paul J Martin; Aimin Huang; Defu Zeng
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 10.  Next generation treatment of acute graft-versus-host disease.

Authors:  J Magenau; P Reddy
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.